Please login to the form below

Not currently logged in
Email:
Password:

James Murdoch to step down from GSK's board

Announcement follows 2011’s damaging revelations of phone hacking at UK newspaper the News of the World

James Murdoch will step down from GlaxoSmithKline's (GSK) board of directors after the pharma company's annual general meeting later this year.

Murdoch is chairman and chief executive of the News Corporation media empire, which faced a series of damaging revelations during 2011 over phone hacking at its UK newspaper the News of the World.

GSK's chairman Sir Christopher Gent said: “James has taken this decision to focus on his current duties as non-executive chairman of BSkyB, and following his decision to re-locate to the US, as chairman and chief executive, international, of News Corporation.

“On behalf of the board, I would like to thank James for the very strong contribution he has made since he was appointed in 2009 and wish him well for the future.”

Other planned changes to GSK's board will see Sir Crispin Davis, Sir Robert Wilson and Larry Culp step down in 2013.

Sir Crispin will be succeeded by Tom de Swaan, who will take over as chairman of the remuneration committee with effect from January 1, 2013, and Judy Lewent, who will take over as chair of the audit and risk committee with effect from the same date.

Meanwhile Sir Deryck Maughan will succeed Sir Robert as senior independent non-executive director with effect from the closure of GSK's annual general meeting in 2013.

31st January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics